Brief: Can-Fite's CF602 Reverses Erectile Dysfunction In Diabetic Pre-Clinical Model Study Published In Peer-Reviewed Journal
24/06/2022 12:05
June 24 (Reuters) - Can Fite Biopharma Ltd CANF.TA :
* CAN-FITE’S CF602 REVERSES ERECTILE DYSFUNCTION IN DIABETIC
PRE-CLINICAL MODEL: STUDY PUBLISHED IN PEER-REVIEWED JOURNAL
ANDROLOGIA
Source text for Eikon: ID:nBw46m4Tpa
Further company coverage: CANF.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Can Fite Biopharma
See all newsBrief: Corrected-Can Fite Biopharma Ltd Files For Offering Of Up To 6.6 mln Ordinary Shares By Selling Shareholders
Can-Fite BioPharma rises after longer-than-anticipated overall survival in ongoing liver cancer study
Can-Fite BioPharma reports longer-than-anticipated overall survival in ongoing liver cancer study
Brief: Can Fite Biopharma Can-Fite Submits Phase 2 Study Protocol For Piclidenoson In Lowe Syndrome
Can-Fite rises as skin drug study reaches interim analysis stage